These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 25338106)

  • 1. Formulation and stability of an extemporaneously compounded oral solution of chlorpromazine HCl.
    Prohotsky DL; Juba KM; Zhao F
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):367-70. PubMed ID: 25338106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of extemporaneously prepared cinacalcet oral suspensions.
    Thomson K; Hutchinson DJ; Chablani L
    Am J Health Syst Pharm; 2018 May; 75(9):e236-e240. PubMed ID: 29691267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of codeine phosphate in an extemporaneously compounded syrup.
    Dentinger PJ; Swenson CF
    Am J Health Syst Pharm; 2007 Dec; 64(24):2569-73. PubMed ID: 18056945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of an extemporaneously compounded baclofen oral liquid.
    Johnson CE; Hart SM
    Am J Hosp Pharm; 1993 Nov; 50(11):2353-5. PubMed ID: 8266961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding.
    Zhao F; Dave VS; Mar MZ; Perri JR
    Int J Pharm Compd; 2018; 22(5):433-439. PubMed ID: 30384342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Simplified Extemporaneously Prepared Potassium Chloride Oral Solution.
    Tannous E; Tal Y; Amarny K
    Int J Pharm Compd; 2016; 20(5):438-439. PubMed ID: 28339380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of extemporaneously prepared rufinamide oral suspensions.
    Hutchinson DJ; Liou Y; Best R; Zhao F
    Ann Pharmacother; 2010 Mar; 44(3):462-5. PubMed ID: 20150505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of extemporaneously prepared rifaximin oral suspensions.
    Cober MP; Johnson CE; Lee J; Currie K
    Am J Health Syst Pharm; 2010 Feb; 67(4):287-9. PubMed ID: 20133533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of extemporaneously prepared moxifloxacin oral suspensions.
    Hutchinson DJ; Johnson CE; Klein KC
    Am J Health Syst Pharm; 2009 Apr; 66(7):665-7. PubMed ID: 19299374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions.
    Kabiche D; Balde IB; Majoul E; Kabiche S; Bourguignon E; Fontan JE; Cisternino S; Schlatter J
    Int J Pharm Compd; 2017; 21(2):160-163. PubMed ID: 28346212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of norfloxacin in an extemporaneously prepared oral liquid.
    Johnson CE; Price J; Hession JM
    Am J Health Syst Pharm; 2001 Apr; 58(7):577-9. PubMed ID: 11296605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of extemporaneously prepared glycopyrrolate oral suspensions.
    Cober MP; Johnson CE; Sudekum D; Penprase K
    Am J Health Syst Pharm; 2011 May; 68(9):843-5. PubMed ID: 21515869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of an extemporaneously compounded terbutaline sulfate oral liquid.
    Horner RK; Johnson CE
    Am J Hosp Pharm; 1991 Feb; 48(2):293-5. PubMed ID: 2003504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of Metronidazole Suspensions.
    Donnelly RF; Ying J
    Int J Pharm Compd; 2015; 19(3):248-51. PubMed ID: 26714365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions.
    Caruthers RL; Johnson CE
    Am J Health Syst Pharm; 2007 Jul; 64(14):1513-5. PubMed ID: 17617502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of levofloxacin in an extemporaneously compounded oral liquid.
    VandenBussche HL; Johnson CE; Fontana EM; Meram JM
    Am J Health Syst Pharm; 1999 Nov; 56(22):2316-8. PubMed ID: 10582824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of dolasetron in two oral liquid vehicles.
    Johnson CE; Wagner DS; Bussard WE
    Am J Health Syst Pharm; 2003 Nov; 60(21):2242-4. PubMed ID: 14619116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of tacrolimus in an extemporaneously compounded oral liquid.
    Jacobson PA; Johnson CE; West NJ; Foster JA
    Am J Health Syst Pharm; 1997 Jan; 54(2):178-80. PubMed ID: 9117806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children.
    Pramann LA; Davidow LW; van Haandel L; Funk RS
    Int J Pharm Compd; 2016; 20(3):257-261. PubMed ID: 28333668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of an extemporaneous alcohol-free melatonin suspension.
    Johnson CE; Cober MP; Thome T; Rouse E
    Am J Health Syst Pharm; 2011 Mar; 68(5):420-3. PubMed ID: 21330684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.